Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allergan falls on delays for wet AMD product

Allergan Inc. (NYSE:AGN) fell $14.88 (13%) to $98.67 on Wednesday after the company disclosed in its 1Q13 earnings that it expects a one to two year

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE